Interaction of perforin and granzyme B and HTLV-1 viral factors is associated with ATL development

Document Type: Original Article


1 Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

2 Hematology Department, Ghaem Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Hematology Department, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): Human T cell leukaemia virus type 1 (HTLV-1) is associated with adult T cell leukaemia (ATL), a malignant lymphoproliferative disease that infects CD4 T cells. It is not clear why the majority of HTLV-1-infected individuals remain asymptomatic carries (ACs) and a minority develop ATL. Cellular immune response has a critical role in ATL and destroys malignant and HTLV-1-infected cells. Perforin and granzyme have important functional roles in apoptosis and destruction of infected cells. In the present study we examined the role of perforin and granzyme in ATL patients and ACs.
Materials and Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from ATL patients and ACs by using Ficoll-hypaque density centrifugation. RNA was extracted and cDNA was synthesized. A real-time PCR TaqMan method was designed and optimized for evaluation of perforin, granzyme, tax, and HBZ gene expression. HTLV-1 proviral load (PVL) was quantified in patients with ATL and ACs.
Results: The mRNA expression of tax and HBZ was significantly higher in ATL patients than ACs (P=0.011 and P=0.0001,respectively). The HTLV-1 PVL was higher in ATL patients compared to with AC group (P=0.015). There was a significant increase in perforin gene expression in ACs compared with ATL patients (P=0.002).  Furthermore, the expression of granzyme was also higher in ACs compared with ATL patients, and significant differences were observed between the two groups (P=0.036).
Conclusion: Low expression of perforin and granzyme in ATL patients seems to influence the efficiency of CTL function and destruction of HTLV-1-infected cells, which might contribute to the disease pathogenesis.


1. Rafatpanah H, Hosseini RF, Pourseyed SH. The Impact of immune response on HTLV-I in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Iran J Basic Med Sci 2013; 16:235-241.
2. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52:172-176.
3. Gonzalez-Alcaide G, Ramos JM, Huamani C, MENDOZA Cd, Soriano V. Human T-lymphotropic virus 1 (HTLV-1) and human T-lymphotropic virus 2 (HTLV-2): geographical research trends and collaboration networks (1989-2012). Rev Inst Med Trop Sao Paulo 2016; 58: 11-19.
4. Gessain A. Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases. Bulletin de la Societe de pathologie exotique (1990) 2011; 104:167-180.
5. Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi Y, Hasegawa H, et al. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int J Oncol 2008; 33:697-703.
6. Fujimoto T, Yamada Y. Clinico-pathological aspects of adult T-cell leukemia/lymphoma (ATL). Nihon Rinsho 2000; 58:655-659.
7. Kokoris SI, Siakantaris MP, Kontopidou FN, Kyrtsonis M-C, Tsakris A, Spanakis N, et al. Adult T-cell leukemia/lymphoma (ATLL): report of two fully documented Hellenic patients. Leuk Lymphoma 2004; 45:715-721.
8. Ghezeldasht SA, Shirdel A, Assarehzadegan MA, Hassannia T, Rahimi H, Miri R, et al. Human T lymphotropic virus type I (HTLV-I) oncogenesis: molecular aspects of virus and host interactions in pathogenesis of adult T cell leukemia/lymphoma (ATL). Iran J Basic Med Sci 2013; 16:179-195.
9. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2010; 30:1379-1389.
10. Enose-Akahata Y, Abrams A, Massoud R, Bialuk I, Johnson KR, Green PL, et al. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. Retrovirology 2013; 10:19-31.
11. Akimoto M, Kozako T, Sawada T, Matsushita K, Ozaki A, Hamada H, et al. Anti‐HTLV‐1 tax antibody and tax‐specific cytotoxic T lymphocyte are associated with a reduction in HTLV‐1 proviral load in asymptomatic carriers. J Med Virol 2007; 79:977-986.
12. Bangham CR, Osame M. Cellular immune response to HTLV-1. Oncogene 2005; 24:6035-6046.
13. Arapović M, Brizić I, Popović B, Jurković S, Jordan S, Krmpotić A, et al. Intrinsic contribution of Perforin to nK-cell homeostasis during Mouse cytomegalovirus infection. Front Immunol 2016; 7:133-142.
14. Liu C-C, Walsh CM, Young JD-E. Perforin: structure and function. Immunol Today 1995; 16:194-201.
15. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003; 193:31-38.
16. Taguchi H, Miyoshi I. Immune suppression in HTLV-I carriers: a predictive sign of adult T-cell leukemia. Acta Medica Okayama 1989; 43:317-321.
17. Kozako T, Arima N, Toji S, Masamoto I, Akimoto M, Hamada H, et al. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol 2006; 177:5718-5726.
18. Sabouri AH, Usuku K, Hayashi D, Izumo S, Ohara Y, Osame M, et al. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)–specific CD8+ T cells in HTLV-1–associated neurologic disease. Blood 2008; 112:2411-2420.
19. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012; 250:87-93.
20. Yu F, Itoyama Y, Fujihara K, Goto I. Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. J Neuroimmunol 1991; 33:121-128.
21. Zhang D, Shankar P, Xu Z, Harnisch B, Chen G, Lange C, et al. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 2003; 101:226-235.
22. Yu F, Itoyama Y, Fujihara K, Goto I. Natural killer (NK) cells in HTLV-I-associated myelopathy/tropical spastic paraparesis—decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. J Neuroimmunol 1991; 33:121-128.
23. Vine AM, Heaps AG, Kaftantzi L, Mosley A, Asquith B, Witkover A, et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol 2004; 173:5121-5129.
24. Pinto MT, Malta TM, Rodrigues ES, Pinheiro DG, Panepucci RA, Malmegrim de Farias KCR, et al. Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4+ T cells in human T Cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients. AIDS Res Hum Retroviruses 2014; 30:610-622.
25. Mohammadi A, Fazeli B, Poursina Z, Tehranian F, Vakili V, Boostani R, et al. HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules. Med Microbiol Immunol 2019; 208:835-844.
26. Mühleisen A, Giaisi M, Köhler R, Krammer P, Li-Weber M. Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression. Cell Death Dis 2014; 5:e1575.
27. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000; 96:275-281.
28. Zhao T, Matsuoka M. HBZ and its roles in HTLV-1 oncogenesis. Front Microbiol 2012; 3:247-252.
29. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
30. Yang OO, Lin H, Dagarag M, Ng HL, Effros RB, Uittenbogaart CH. Decreased perforin and granzyme B expression in senescent HIV-1-specific cytotoxic T lymphocytes. Virology 2005; 332:16-19.
31. Zhang Y, Wallace DL, De Lara CM, Ghattas H, Asquith B, Worth A, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 2007; 121:258-265.